Types and Uses of Cost-Effectiveness Models
Cost-Effectiveness Models: A Strategic Tool for Pricing and Market Access
In today’s market, clinical efficacy alone is rarely enough to differentiate a product. Payers, health systems, and policy bodies want to know: Is the price justified by the value delivered? Cost-effectiveness modeling provides a structured way to answer that question by connecting clinical outcomes to economic consequences. It estimates how much additional health benefit a therapy delivers relative to its cost. For pharmaceutical and biotechnology companies, this is not simply an academic exercise. It is a critical tool to defend price, support access, and shape value narratives.
The Role of Cost-Effectiveness in the U.S. and Globally
lobally, cost-effectiveness evidence is central to health technology assessment (HTA). In many countries, reimbursement decisions explicitly consider cost-effectiveness in pricing and coverage decisions.
In the United States, organizations such as the Institute for Clinical and Economic Review (ICER) conduct cost-effectiveness evaluations that influence payer negotiations and public perception of value. Even when not formally binding, these assessments can shape contracting strategies and formulary positioning.
Although it has played a more limited role in formal coverage decisions, drug pricing reform is likely to bring cost-effectiveness research to the forefront. Proposals such as international reference pricing or “most favored nation” approaches would tie U.S. drug prices to those paid in other countries, many of which rely on HTA and cost-effectiveness evaluations to determine price. In such an environment, cost-effectiveness assessments conducted abroad would influence pricing expectations in the U.S. making it increasingly important for manufacturers to use cost-effectiveness evidence to shape perceptions of value.
Why Modeling Is Essential
Cost-effectiveness models allow manufacturers to:
In short, modeling helps articulate why a therapy’s price reflects its overall impact not just its acquisition cost.
Different Models for Different Strategic Questions
Not all models are structured the same way. The choice of model reflects the disease area, complexity of care pathways, and the specific commercial question at hand.
Decision Tree Models are well suited for short-term decisions or acute conditions. They provide clarity and transparency, making them especially useful for early value assessments or products with near-term outcomes.
Budget Impact Models address affordability, demonstrating that price is manageable within existing budgets. They are an essential complement in high-cost or rapidly growing therapeutic areas, particularly at launch when payer decisions are heavily influenced by near-term spending implications.
Markov Models are commonly used in chronic or progressive diseases, to simulate patients moving between health states over time. They are particularly valuable when demonstrating long-term survival gains or delayed disease progression. These elements are critical to justify premium pricing in oncology, cardiovascular, and specialty markets.
Discrete-Event Simulation (DES) models individual patient journeys and timing of events for complex treatment pathways or heterogenous patient populations. Their flexibility is especially useful when timing, operational complexity, or diverse patient profiles materially affect value as is often the case in specialty or high-cost disease areas.
Perspective Matters: Payer vs. Societal Value
Another key decision is perspective. A payer-focused model typically includes direct medical costs and budget impact. A societal perspective may incorporate productivity gains, caregiver burden, and indirect costs. Depending on the therapy, these broader elements may significantly strengthen the value case especially for diseases affecting working-age populations. Choosing the right perspective ensures the model aligns with the audience you are trying to persuade.
When Is It Worth Doing?
Cost-effectiveness models allow teams to test pricing scenarios before launch. What happens to the value proposition at different price points? How sensitive are results to uptake assumptions or durability of effect? These insights can inform pricing strategy and risk-sharing discussions. They are especially valuable when:
A Strategic Asset, Not Just an Academic Exercise
When developed early and aligned with clinical strategy, cost-effectiveness modelling becomes a strategic asset helping to shape trial design, evidence generation, pricing scenarios, and payer engagement plans. In an environment where stakeholders increasingly demand proof of value, well-designed models provide a defensible framework for explaining why a product is worth its price.
If you fail to define the value story using robust economic evidence, others may define it for you.
Partner with Magnolia Market Access
Our team can work with you to design and execute the right analysis for you. Contact us to support your modeling work.
Related Content: